Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 970-976

  Wimazal, F ^a   Sperr, W R ^a   Kundi, M ^a   Vales, A ^a   Fonatsch, C ^a   Thalhammer Scherrer, R ^a   Schwarzinger, I ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

IPSS; LDH; MDS; Prognosis

Indexed keywords

LACTATE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE MARROW; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 43049086337     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm595     Document Type: Article

References (30)

1. Cazzola M, Riccardi A. Myelodysplastic syndromes: Biologic and clinical aspects. Haematologica, 1986; 71: 147-159.
2. Alessandrino EP, Amadori S, Cazzola M et al. Myelodysplastic syndromes: recent advances. Haematologica 2001; 86: 1124-1157.
3. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16.
4. Bennett JM, Komrokji RS. The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment. Hematology 2005; 10: 258-269.
5. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
6. Bennett JM, Catovsky D, Daniel MT et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87: 746-754.
7. Brunning RD, Bennett JM, Flandrin G et al. Myelodysplastic syndromes. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): Tumours of Haematopoietic and Lymphoid Tissues, Pathology & Genetics, World Health Organization Classification of Tumours. Lyon, France: IARC Press 2001; 61-73.
8. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005; 32: 3-10.
9. Morel P, Hebbar M, Lai JL et al. Cylogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7: 1315-1323.
10. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
11. Toyama K, Ohyashiki K, Yoshida Y et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia 1993; 7: 499-508.
12. Aul C, Gattermann N, Heyll A et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patents and proposals for an improved scoring system. Leukemia 1992; 6: 52-59.
13. Mufti GJ, Stevens A. Oscier DG et al. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
14. Greenberg P, Cox C, LeBeau MM et al. International scoring system, for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
15. Malcovati L, Germing U, Kündgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
16. Aul C, Gattermann N, Germing U et al. Risk assessment in primary myelodysplastic syndromes: Validation of the Düsseldorf score. Leukemia 1994; 8: 1906-1913.
17. Wimazal F, Sperr WR, Kundi M et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 2001; 25: 287-294.
18. Germing U, Hildebrandt B, Pfellstocker M et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patents with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.
19. Fonatsch C, Gudat H, Lengfelder E et al, Correlation of cytogenetic findings with clinical features in 18 patents with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8: 1318-1326.
20. ISCN. An international system for human cylogenetic nomenclature. Cytogenet Cell Genet 1981; 31: 5.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 157.
22. Iwanaga M, Furukawa K, Amenomori T et al. Paroxysmal nocturnal haemoglobinuda clones in patents with myelodysplastic syndromes. Br J Haematol 1998; 102: 465-474.
23. Oelschlaegel U, Besson I, Amoulet C et al. A standardized flow cytometric method for screening paroxysmal nocturnal haemoglubinuria (PNH) measuring CD55 and CD59 expression on erythrocytes, and granulocytes. Clin Lab Haematol 2001; 23: 81-90.
24. Tomonaga M, Tomonaga Y, Kusano M, Ichimaru M, Sequential karyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome. Br J Haematol 1984; 58: 53-60.
25. Tricot G, Boogaerts MA, De Wolf-Peeters C et al. The myelodysplastic syndromes: Differrent evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985; 59: 659-670.
26. Haase D, Fonatsch C, Freund M. Karyotype Instability in myelodysplastic syndromes-a specific step in pathogenesis preceding clonal chromosome anomalies. Leuk Lymphom 1992; 8: 221-228.
27. Cutler CS, Lee SJ, Greenberg P et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585.
28. Deeg HJ. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematology Am Soc Hematol Educ Program 2005; 1: 167-173.
29. List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
30. Valent P, Horny HP, Bennett JM et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.